RU2676303C2 - Использование антагониста vegf для лечения ретролентальной фиброплазии - Google Patents

Использование антагониста vegf для лечения ретролентальной фиброплазии Download PDF

Info

Publication number
RU2676303C2
RU2676303C2 RU2016104398A RU2016104398A RU2676303C2 RU 2676303 C2 RU2676303 C2 RU 2676303C2 RU 2016104398 A RU2016104398 A RU 2016104398A RU 2016104398 A RU2016104398 A RU 2016104398A RU 2676303 C2 RU2676303 C2 RU 2676303C2
Authority
RU
Russia
Prior art keywords
treatment
ranibizumab
vegf antagonist
vegf
infants
Prior art date
Application number
RU2016104398A
Other languages
English (en)
Russian (ru)
Other versions
RU2016104398A3 (https=
RU2016104398A (ru
Inventor
Габриэла БУРЬЯН
Сергей АКСЕНОВ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2016104398A publication Critical patent/RU2016104398A/ru
Publication of RU2016104398A3 publication Critical patent/RU2016104398A3/ru
Application granted granted Critical
Publication of RU2676303C2 publication Critical patent/RU2676303C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
RU2016104398A 2013-07-11 2014-07-10 Использование антагониста vegf для лечения ретролентальной фиброплазии RU2676303C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11
US61/845,073 2013-07-11
PCT/IB2014/063003 WO2015004626A2 (en) 2013-07-11 2014-07-10 Use of a vegf antagonist in treating retinopathy of prematurity

Publications (3)

Publication Number Publication Date
RU2016104398A RU2016104398A (ru) 2017-08-16
RU2016104398A3 RU2016104398A3 (https=) 2018-05-31
RU2676303C2 true RU2676303C2 (ru) 2018-12-27

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016104398A RU2676303C2 (ru) 2013-07-11 2014-07-10 Использование антагониста vegf для лечения ретролентальной фиброплазии

Country Status (14)

Country Link
US (1) US20160159893A1 (https=)
EP (1) EP3019527A2 (https=)
JP (1) JP2016523956A (https=)
KR (1) KR20160030504A (https=)
CN (1) CN105377890A (https=)
AR (1) AR096893A1 (https=)
AU (3) AU2014288847A1 (https=)
BR (1) BR112016000282A2 (https=)
CA (1) CA2917813A1 (https=)
HK (1) HK1221231A1 (https=)
MX (1) MX2016000385A (https=)
RU (1) RU2676303C2 (https=)
TW (1) TW201536317A (https=)
WO (1) WO2015004626A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2846105C1 (ru) * 2020-09-03 2025-08-29 Юниверсити Оф Массачусеттс Аденоассоциированный вирус для доставки kh902 (конберцепта) и его применения

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
EP3397271B1 (en) 2015-12-30 2021-11-03 Marshall University Research Corporation Compositions and methods for treating retinopathy
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2217329B1 (en) * 2007-11-07 2018-01-10 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
US20140249191A1 (en) * 2011-10-20 2014-09-04 Avienne Pharmaceuticals Gmbh Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases
KR102083700B1 (ko) * 2012-08-21 2020-03-02 옵코 파마슈티칼스, 엘엘씨 리포좀 제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHUN-JU LIN et al. EFFECTS OF RANIBIZUMAB ON VERY LOW BIRTH WEIGHT INFANTS WITH STAGE 3 RETINOPATHY OF PREMATURITY: A PRELIMINARY REPORT/ Taiwan Journal of Ophthalmology, V.2, 25.11.12, стр. 136-139. *
CHUN-JU LIN et al. EFFECTS OF RANIBIZUMAB ON VERY LOW BIRTH WEIGHT INFANTS WITH STAGE 3 RETINOPATHY OF PREMATURITY: A PRELIMINARY REPORT/ Taiwan Journal of Ophthalmology, V.2, 25.11.12, стр. 136-139. RADHA P. KOHLY et al. MANAGEMENT OF PEDIATRIC CHOROIDAL NEOVASCULAR MEMBRANES WITH INTRAVITREAL ANTI-VEGF AGENTS: A RETROSPECTIVE CONSECUTIVE CASE SERIES/ Canadian Journal of Ophthalmology, 2011, V.46. RUDOLF AUTRATA et al. INTRAVITREAL PEGAPTANIB COMBINED WITH DIODE LASER THERAPY FOR STAGE 3+ RETINOPATHY OF PREMATURITY IN ZONE I AND POSTERIOR ZONE II/ European Journal of Ophthalmology, 2012, V.22. *
RADHA P. KOHLY et al. MANAGEMENT OF PEDIATRIC CHOROIDAL NEOVASCULAR MEMBRANES WITH INTRAVITREAL ANTI-VEGF AGENTS: A RETROSPECTIVE CONSECUTIVE CASE SERIES/ Canadian Journal of Ophthalmology, 2011, V.46. *
RUDOLF AUTRATA et al. INTRAVITREAL PEGAPTANIB COMBINED WITH DIODE LASER THERAPY FOR STAGE 3+ RETINOPATHY OF PREMATURITY IN ZONE I AND POSTERIOR ZONE II/ European Journal of Ophthalmology, 2012, V.22. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2846105C1 (ru) * 2020-09-03 2025-08-29 Юниверсити Оф Массачусеттс Аденоассоциированный вирус для доставки kh902 (конберцепта) и его применения

Also Published As

Publication number Publication date
AU2014288847A1 (en) 2016-01-28
WO2015004626A3 (en) 2015-05-28
TW201536317A (zh) 2015-10-01
JP2016523956A (ja) 2016-08-12
RU2016104398A3 (https=) 2018-05-31
CA2917813A1 (en) 2015-01-15
KR20160030504A (ko) 2016-03-18
BR112016000282A2 (pt) 2017-12-12
HK1221231A1 (zh) 2017-05-26
EP3019527A2 (en) 2016-05-18
WO2015004626A2 (en) 2015-01-15
AU2017204326A1 (en) 2017-07-13
MX2016000385A (es) 2016-04-29
RU2016104398A (ru) 2017-08-16
US20160159893A1 (en) 2016-06-09
AR096893A1 (es) 2016-02-03
CN105377890A (zh) 2016-03-02
AU2019206000A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
RU2676303C2 (ru) Использование антагониста vegf для лечения ретролентальной фиброплазии
RU2676274C2 (ru) Применение антагониста vegf при лечении хориоретинальных неоваскулярных нарушений и нарушений проницаемости у педиатрических пациентов
Moshfeghi et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four–week results of an uncontrolled open-label clinical study
Diabetic Retinopathy Clinical Research Network A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
CA2834373A1 (en) Method of treating vision disorders
Yang et al. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy
Chan et al. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)
RS67369B1 (sr) Produženi režimi antagonista vegf u visokim dozama za lečenje angiogenih očnih poremećaja
Lorenz et al. A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma–the STRONG study: study protocol for a randomised controlled trial
Mete et al. Does ranibizumab (Lucentis®) change retrobulbar blood flow in patients with neovascular age-related macular degeneration?
Noma et al. Intravitreal ranibizumab and aqueous humor factors/cytokines in major and macular branch retinal vein occlusion
EP3934682A1 (en) Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
Ren et al. Two different initial treatment regimens of Conbercept in diabetic macular edema: 12-month results from a multicenter randomized controlled study
Tian et al. Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib
Deák et al. Refractive changes after pharmacologic resolution of diabetic macular edema
Studnička et al. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice
Jiang et al. Jiang et al. BMC Ophthalmology (2020) 20: 43
Silva et al. A 24-month evaluation of aflibercept for wet age-related macular degeneration in patients previously receiving ranibizumab or bevacizumab
Flach et al. Katrin Lorenz1, Yvonne Scheller1, Katharina Bell1, Franz Grus1, Katharina A. Ponto1, 2, Felix Bock3, Claus Cursiefen3
NZ616353B2 (en) Method of treating vision disorders
Ozdek et al. Re-Treatment Strategies for Neovascular AMD hen to Treat hen to Stop

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200711